Biotechnology New Hope for Aggressive Lung Cancer: AstraZeneca’s Imfinzi Shows Promising Results in Phase 3 Trial – AstraZeneca (NASDAQ:AZN) Read more
Stockmarkets US FDA approves Merck’s therapy for rare lung condition Reuters via biedexmarkets.com Read more
Biotechnology After Failed Prostate Cancer Study Merck’s Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study – Merck & Co (NYSE:MRK) Read more
Biotechnology Vertex Pharmaceuticals’ Triple Combo Treatment For Lung Disorder Meets Primary Goal In Adult And Pediatric Patients – Vertex Pharmaceuticals (NASDAQ:VRTX) Read more